# Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

> **NCT00003809** · PHASE3 · COMPLETED · sponsor: **Eastern Cooperative Oncology Group**

## Conditions studied

- Head and Neck Cancer

## Interventions

- **BIOLOGICAL:** cetuximab
- **DRUG:** cisplatin

## Key facts

- **NCT ID:** NCT00003809
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-08-06
- **Primary completion:** 2004-09
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003809, "Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00003809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*